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Abstract For the purpose of a nationwide surveillance of 
the antimicrobial susceptibility of bacterial respiratory 
pathogens in patients in Japan, the Japanese Society of 
Chemotherapy conducted their second year survey, during 
the period from January to August, 2007. A total of 1178 
strains were collected from clinical specimens obtained 
from adult patients with well-diagnosed respiratory tract 
infections. Susceptibility testing was evaluable for 1108 
strains (226 Staphylococcus aureus, 257 Streptococcus pneu-
moniae, 6 Streptococcus pyogenes, 206 Haemophilus inﬂ u-
enzae, 120 Moraxella catarrhalis, 122 Klebsiella pneumoniae, 
and 171 Pseudomonas aeruginosa). A total of 44 antibacte-
rial agents, including 26 β-lactams (four penicillins, three 
penicillins in combination with β-lactamase inhibitors, four 
oral cephems, eight parenteral cephems, one monobactam, 
ﬁ ve carbapenems, and one penem), three aminoglycosides, 
four macrolides (including ketolide), one lincosamide, one 
tetracycline, two glycopeptides, six ﬂ uoroquinolones, and 
one oxazolidinone were used for the study. Analysis was 
conducted at the central reference laboratory according to 
the method recommended by the Clinical and Laboratory 
Standards Institute (CLSI). The incidence of methicillin-
resistant Staphylococcus aureus (MRSA) was high, at 
59.7%, and the incidences of penicillin-intermediate-
resistant and -resistant Streptococcus pneumoniae (PISP 
and PRSP) were 30.4% and 5.1%, respectively. Among 
Haemophilus inﬂ uenzae strains, 19.9% of them were found 
to be β-lactamase-non-producing ampicillin (ABPC)-inter-
mediately-resistant (BLNAI), 29.1% to be β-lactamase-
non-producing ABPC-resistant (BLNAR), and 6.7% to be 
β-lactamase-producing ABPC-resistant (BLPAR) strains. 
Extended-spectrum β-lactamase-producing Klebsiella 
pneumoniae was not isolated. Two isolates (1.2%) of 
Pseudomonas aeruginosa were found to be metallo-β-
lactamase-producing strains, including one (0.6%) sus-
pected multidrug-resistant strain showing resistance to 
imipenem, amikacin, and ciproﬂ oxacin. These data will be 
a useful reference for future periodic surveillance studies 
and for investigations to control resistant infections as well. 
Continued surveillance is required to prevent the further 
spread of these antimicrobial resistances.
Key words Surveillance · Susceptibility · Resistance · Respi-
ratory tract infection
Introduction
In order to investigate trends and changes in bacterial 
pathogens and the emergence of resistance among them, 
the Japanese Society of Chemotherapy (JSC) established a 
nationwide surveillance network in 2006. The ﬁ rst survey 
was conducted during the period from January to August, 
2006, with the cooperation of 32 medical institutions 
throughout Japan, and we reported trends in the antimicro-
bial susceptibilities of bacterial species from patients with 
respiratory tract infections (RTIs).1 The ﬁ rst surveillance, 
with a total of 924 strains, revealed the incidence of 
methicillin-resistant Staphylococcus aureus (MRSA) as 
63.4%, penicillin-intermediate-resistant and -resistant 
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Streptococcus pneumoniae (PISP and PRSP) as 35.0% and 
4.0%, respectively, and β-lactamase-non-producing ABPC-
resistant (BLNAR) and β-lactamase-producing ABPC-
resistant (BLPAR) strains of Haemophilus inﬂ uenzae as 
29.1% and 4.8%, respectively. The incidence of extended-
spectrum β-lactamase-producing Klebsiella pneumoniae 
was low, at 2.7%; and 2.1% of Pseudomonas aeruginosa 
were found to be metallo-β-lactamase-producing strains.
Here we report the study of the second year nationwide 
surveillance conducted by the JSC. The results obtained 
from this surveillance will be used as a set of controls for 
surveillance studies to be conducted in the future by the 
JSC and by other organizations as well.
Materials and methods
Strains and quality control
The causative bacteria from patients with RTI were isolated 
from sputum, specimens collected by transtracheal aspira-
tion, or bronchoscopy. Identiﬁ cation of a causative patho-
gen of RTI was evaluated by quantitative culture and Gram 
staining, or by other means, at the 39 participating medical 
institutions (listed in Table 1). These bacteria were identi-
ﬁ ed at the species level, suspended in preservation-broth 
contained in Micro-bank tubes (Asuka Junyaku, Tokyo, 
Japan) at each institution, and sent to the central labora-
tory, the Research Center for Anti-infective Drugs of the 
Kitasato Institute (hereafter referred to as the Center), in 
containers kept at −20°C. Electronic uniform data sheets for 
each patient from whom these strains were isolated were 
also completed at each institution and sent to the Center so 
that the microbiological data obtained were able to be strat-
iﬁ ed according to the settings and proﬁ les of the patients 
and the diagnoses.
A total of 1178 strains were received at the Center and 
kept at −80°C until the antimicrobial susceptibility testing 
was conducted. Re-identiﬁ cation and cultivation of the 
strains gave 1108 evaluable strains, consisting of 226 S. 
aureus, 257 S. pneumoniae, 6 S. pyogenes, 206 H. inﬂ uenzae, 
120 M. catarrhalis, 122 K. pneumoniae and 171 P. 
aeruginosa.
The accuracy of the determination of the minimum 
inhibitory concentrations (MICs) of antibacterial agents 
was controlled according to the recommendations of the 
Clinical and Laboratory Standards Institute (CLSI), using 
Table 1. List of participating institutions contributing to our surveillancea
Ehime Prefectural Central Hospital, Matsuyama, Ehime
Faculty of Medicine University Hospital, Kagawa University,
Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa
Fukushima Prefectural Aizu General Hospital, Aizuwakamatsu, Fukushima
Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka
Hiroshima Prefectural Hospital, Hiroshima, Hiroshima Hospital of the Kinki University School of Medicine, Osakasayama, Osaka
Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi
International Medical Center of Japan, Shinjuku, Tokyo
Iwate Prefectural Central Hospital, Morioka, Iwate
Japanese Red Cross Sendai Hospital, Sendai, Miyagi
Kasugai Municipal Hospital, Kasugai, Aichi
Kawasaki Medical School Hospital, Kurashiki, Okayama
Kurume University School of Medicine, Kurume, Fukuoka
Kyorin University Hospital, Mitaka, Tokyo
Matsue Red Cross Hospital, Matsue, Shimane
Nagasaki University School of Medicine, Nagasaki, Nagasaki
National Hospital Organization Tokyo Medical Center, Meguro, Tokyo
Niigata City General Hospital, Niigata, Niigata
Niigata University Medical and Dental Hospital, Niigata, Niigata
Okayama University Hospital, Okayama, Okayama
Osaka-City General Hospital, Miyakojima, Osaka
Oita University Faculty of Medicine, Yufu, Oita
Saga Medical School Faculty of Medicine, Saga University, Saga, Saga
St. Luke’s International Hospital, Chuo, Tokyo
Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto
Saka General Hospital, Shiogama, Miyagi
Sanyudo Hospital, Yonezawa, Yamagata
Sendai Kousei Hospital, Sendai, Miyagi
Shimonoseki City Hospital, Shimonoseki, Yamaguchi
Shinrakuen Hospital, Niigata, Niigata
South Miyagi Medical Center, Ogawara, Miyagi
Tokyo Metropolitan Toshima Hospital, Toshima, Tokyo
Tottori University Hospital, Yonago, Tottori
Toyama Prefectural Central Hospital, Toyama, Toyama
Yamagata Saisei Hospital, Yamagata, Yamagata
Yamanashi Red Cross Hospital, Fujikawaguchiko, Yamanashi
a City and prefecture locations are shown
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the following control strains, respectively: S. aureus 
ATCC29213 and Escherichia coli ATCC35218 for clinical 
isolates of S. aureus and M. catarrhalis; S. pneumoniae 
ATCC49619 for clinical isolates of S. pneumoniae and 
S. pyogenes; H. inﬂ uenzae ATCC49247, ATCC49766, and 
E. coli ATCC35218 for clinical isolates of H. inﬂ uenzae; 
E. coli ATCC25922 and ATCC35218 for clinical isolates of 
K. pneumoniae; and P. aeruginosa ATCC27853, E. coli 
ATCC25922, and ATCC35218 for clinical isolates of P. 
aeruginosa. E. coli ATCC35218 was used as a control strain 
for the determination of the MICs of β-lactam antibiotics 
combined with β-lactamase inhibitors.
Susceptibility testing and MIC determination
Susceptibility testing was performed according to the CLSI 
(formerly NCCLS) standards M7-A72 for the microbroth 
dilution method. In brief, cation-adjusted Mueller-Hinton 
broth (25 mg/L Ca2+ and 12.5 mg/L Mg2+; CA-MH broth) 
was used to measure MICs against S. aureus, M. catarrhalis, 
K. pneumoniae, and P. aeruginosa. For the determination 
of the MIC of oxacillin, 2% NaCl was added to CA-MH 
broth. For the determination of MICs against S. pneumoniae 
and S. pyogenes, 3.3% lysed horse blood (LHB) was added 
to the CA-MH broth. Haemophilus Test Medium (HTM) 
broth was used for H. inﬂ uenzae.
A 0.005-ml portion of test organism solution, grown to 
turbidity of MacFarland number 0.5 and diluted tenfold 
with saline, was inoculated to either CA-MH broth or HTM 
broth to make a ﬁ nal volume of 0.1 ± 0.02 ml. The broth 
was poured into a well in a microplate where the serially 
diluted freeze-dried test agent was placed, and the MIC was 
determined by using the MIC2000 system (Eiken Kagaku, 
Tokyo, Japan).
Antibacterial agents
Susceptibilities of the bacterial strains were tested for the 
following 44 antimicrobial agents: four penicillins: benzyl-
penicillin (PCG; Meiji Seika, Tokyo, Japan), oxacillin 
(MPIPC; Meiji), ampicillin (ABPC; Meiji), and piperacillin 
(PIPC; Toyama Chemical, Tokyo, Japan); three penicillins 
in combination with β-lactamase inhibitors: clavulanic acid-
amoxicillin (CVA/AMPC; Glaxo SmithKline, Japan, Tokyo, 
Japan), sulbactam-ABPC (SBT/ABPC; Pﬁ zer Japan, Tokyo, 
Japan), and tazobactam-PIPC (TAZ/PIPC; Toyama); four 
oral cephems: cefaclor (CCL; Shionogi, Tokyo, Japan), 
cefdinir (CFDN; Astellas Pharma, Tokyo, Japan), cefcap-
ene (CFPN; Shionogi), and cefditoren (CDTR; Meiji); eight 
parenteral cephems: cefazolin (CEZ; Astellas), cefoxitin 
(CFX; Banyu Pharmaceutical, Tokyo, Japan), cefmetazole 
(CMZ; Daiichi-Sankyo, Tokyo, Japan), cefotiam (CTM; 
Takeda Pharmaceutical, Tokyo, Japan), ceftazidime (CAZ; 
Glaxo SmithKline), ceftriaxone (CTRX; Chugai Pharma-
ceutical, Tokyo, Japan), cefepime (CFPM; Meiji), and cefo-
zopran (CZOP; Takeda); a monobactam: aztreonam (AZT; 
Eisai, Tokyo, Japan); ﬁ ve carbapenems: imipenem (IPM; 
Banyu, Tokyo, Japan), panipenem (PAPM; Daiichi-
Sankyo), meropenem (MEPM; Dainippon Sumitomo 
Pharma, Tokyo, Japan), biapenem (BIPM; Meiji), and 
doripenem (DRPM; Shionogi); one penem: faropenem 
(FRPM; Maruho, Tokyo, Japan); three aminoglycosides: 
gentamicin (GM; Shionogi), amikacin (AMK; Banyu), and 
arbekacin (ABK; Meiji); four macrolides: erythromycin 
(EM; Dainippon Sumitomo), clarithromycin (CAM; 
Toyama), azithromycin (AZM; Pﬁ zer), and telithromycin 
(TEL; Sanoﬁ -Aventis, Tokyo, Japan); a lincosamide: clinda-
mycin (CLDM; Dainippon Sumitomo); a tetracycline: mino-
cycline (MINO; Wyeth, Madison, NJ, USA/Takeda); two 
glycopeptides: vancomycin (VCM; Shionogi) and teico-
planin (TEIC; Astellas); six ﬂ uoroquinolones: ciproﬂ oxacin 
(CPFX; BayerYakuhin, Tokyo, Japan), levoﬂ oxacin (LVFX; 
Daiichi-Sankyo), tosuﬂ oxacin (TFLX; Toyama), gatiﬂ o-
xacin (GFLX; Kyorin Pharmaceutical, Tokyo, Japan), 
moxiﬂ oxacin (MFLX; Shionogi), and pazuﬂ oxacin (PZFX; 
Toyama); and an oxazolidinone: linezolid (LZD; Pﬁ zer). 
These antimicrobial agents were serially diluted and placed 
in a freeze-dried state in the respective wells of microplates. 
The stability of the antimicrobial agent-containing micro-
plates was guaranteed by the manufacturer (Eiken Kagaku) 
for 9 months.
Detection of β-lactamases
To detect β-lactamases in H. inﬂ uenzae, tests with Nitroce-
ﬁ n disks (Kanto Chemical, Tokyo, Japan) were conducted 
according to the reference manual supplied by the 
manufacturer.
A recently established rapid detection method, Cica-
Beta Test 1 (Kanto Chemical), designed to detect extended-
spectrum β-lactamase (ESBL) and metallo-β-lactamase 
(MBL) directly in colonies of Gram-negative rods,3,4) was 
employed to identify K. pneumoniae and P. aeruginosa 
strains which produce such β-lactamases.
Results
Findings for Staphylococcus aureus
S. aureus was the species with the greatest number (226/1108; 
20.4 %) among the evaluable strains in this investigation. 
The in-vitro antimicrobial susceptibilities, given as MIC50 
⁄MIC90 values and MIC ranges, for S. aureus isolates are 
shown in Table 2. The susceptibility of these S. aureus 
strains against 43 antibacterial agents revealed that 135 
strains (59.7%) were methicillin-resistant S. aureus (MRSA; 
MIC of MPIPC ≥ 4 μg/ml).
Susceptibility of methicillin-susceptible S. aureus (MSSA)
The MIC90s of penicillins, except for oxacillin, against 91 
MSSA strains were 16–32 μg/ml; however, the MICs in 
combinations with β-lactamase inhibitors (CVA/AMPC, 
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SBT/ABPC, and TAZ/PIPC) decreased to 1.0–2.0 μg/ml. 
The MIC90s of CCL, CAZ, CTRX, CFPM, and CMZ ranged 
from 2.0 to 8.0 μg/ml and those of the rest of the six cephems 
ranged from 0.25 to 1.0 μg/ml. Carbapenems showed the 
strongest activity, with MIC90s of ≤0.125 μg/ml. As for the 
aminoglycosides, GM, AMK, and ABK showed MIC90s of 
8.0, 4.0, and 0.5 μg/ml, respectively. Among the macrolide-
lincosamide antibiotics, TEL and CLDM showed relatively 
strong activity, with an MIC90 of 0.25 μg/ml, but the rest of 
the macrolides showed weak activity, with MIC90s of 
≥128 μg/ml. Relatively strong activities of MINO, VCM, 
TEIC, and all six ﬂ uoroquinolones, with MIC90s of 0.125–
1.0 μg/ml, were noted.
Susceptibility of MRSA
Only 4 of the 43 antibacterial agents tested, ABK, VCM, 
TEIC, and LZD, showed appreciable activity against 
MRSA, with MIC90s of ≤2.0 μg/ml. The other 39 agents 
showed weak or almost no activity, with MIC90s of 16– 
≥256 μg/ml against these MRSA strains.
Findings for Streptococcus pneumoniae
The susceptibilities of the 257 strains of S. pneumoniae to 
40 antimicrobial agents were measured, and 166 (64.6%) of 





MSSA (MPIPC 2 μg/ml)
n = 91
MRSA (MPIPC 4 μg/ml)
n = 135
MIC (μg/ml) MIC (μg/ml) MIC (μg/ml)
50% 90% Range 50% 90% Range 50% 90% Range
PCG 16 32 0.06–128 0.25 16 0.06–64 16 64 4–128
ABPC 16 64 0.125–128 1 16 0.125–64 32 64 8–128
SBT/ABPC 8 32 0.125–64 0.5 2 0.125–4 16 32 2–64
CVA/AMPC 16 32 0.125–128 0.5 1 0.125–8 32 64 2–128
PIPC 64 256 0.5–256 2 32 0.5–128 128 256 16–256
TAZ/PIPC 64 128 0.25–256 0.5 2 0.25–4 64 128 4–256
CCL 64 256 0.5–256 1 2 0.5–8 128 256 8–256
CFDN 128 128 0.125–128 0.25 0.25 0.125–0.5 128 128 0.5–128
CFPN 256 256 0.25–256 1 1 0.25–2 256 256 2–256
CDTR 64 128 0.25–128 0.5 0.5 0.25–1 64 128 2–128
CEZ 128 256 0.25–256 0.5 0.5 0.25–2 256 256 1–256
CTM 128 256 0.25–256 0.5 1 0.25–1 256 256 2–256
CAZ 128 128 4–128 8 8 4–16 128 128 16–128
CTRX 256 256 2–256 4 4 2–8 256 256 8–256
CFPM 128 256 0.5–256 2 4 0.5–4 128 256 4–256
CZOP 16 64 0.5–256 0.5 1 0.5–2 32 64 2–256
CMZ 32 64 0.5–128 1 2 0.5–4 32 128 4–128
IPM 16 64 0.06–128 0.06 0.125 0.06–0.25 32 64 0.06–128
PAPM 8 32 0.06–256 0.06 0.125 0.06–0.5 16 32 0.125–256
MEPM 8 32 0.06–64 0.125 0.125 0.06–0.25 16 32 0.25–64
BIPM 16 64 0.06–128 0.06 0.06 0.06–0.125 32 64 0.125–128
DRPM 4 16 0.06–32 0.06 0.06 0.06–0.125 8 32 0.125–32
FRPM 128 256 0.125–256 0.125 0.25 0.125–0.5 256 256 0.25–256
GM 0.5 128 0.25–256 0.5 8 0.25–256 16 128 0.25–256
AMK 4 16 1–256 2 4 2–64 16 32 1–256
ABK 0.5 1 0.25–8 0.5 0.5 0.25–8 0.5 2 0.25–4
CPFX 8 128 0.125–256 0.25 1 0.125–64 128 128 0.25–256
LVFX 4 256 0.125–256 0.25 0.5 0.125–16 32 256 0.25–256
TFLX 4 32 0.06–32 0.06 0.125 0.06–32 32 32 0.06–32
GFLX 1 64 0.06–256 0.06 0.125 0.06–4 8 64 0.06–256
PZFX 4 256 0.125–256 0.25 0.25 0.125–8 8 256 0.125–256
MFLX 1 32 0.06–64 0.06 0.125 0.06–4 4 32 0.06–64
MINO 0.5 16 0.06–16 0.125 0.125 0.06–16 8 16 0.125–16
EM 256 256 0.5–256 0.5 256 0.5–256 256 256 0.5–256
CAM 128 128 0.125–128 0.25 128 0.125–128 128 128 0.25–128
AZM 128 128 0.25–128 0.5 128 0.25–128 128 128 0.5–128
TEL 64 64 0.06–64 0.125 0.25 0.06–64 64 64 0.125–64
CLDM 256 256 0.06–256 0.25 0.25 0.06–256 256 256 0.125–256
VCM 1 2 0.5–2 1 1 0.5–2 1 2 0.5–2
TEIC 1 2 0.125–4 1 1 0.25–2 1 2 0.125–4
LZD 2 2 1–4 2 4 1–4 2 2 1–4
MPIPC 128 256 0.125–256 0.25 0.5 0.125–2 256 256 4–256
CFX 128 256 2–256 2 4 2–4 128 256 8–256
Susceptibilities of the 226 strains of S. aureus to 43 antimicrobial agents were measured. The strains consisted of 135 strains (59.7%) of MRSA 
and 91 strains (40.3%) of MSSA
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them were identiﬁ ed as penicillin-susceptible (PSSP), 78 
(30.4%) as penicillin-intermediate (PISP), and 13 (5.1%) as 
penicillin-resistant strains (PRSP) according to the break-
point for PCG deﬁ ned by the CLSI standards.2
The Food and Drug Administration (FDA) has amended 
the breakpoints for penicillin in the treatment of pneumo-
coccal pneumonia, as follows: the MICs of susceptible (S), 
intermediate (I), and resistant (R) strains are ≤2, 4, and 
≥8 μg/ml, respectively. With the new criteria for breakpoint 
MICs, the 257 pneumococcal strains were classiﬁ ed as 256 
(99.6%) susceptible strains, and only 1 (0.4%) intermediate 
strain. We did not ﬁ nd resistant pneumococcal strains that 
showed MIC ≥ 8 μg/ml.
Two cephems, CFPN and CDTR, all ﬁ ve carbapenems, 
both glycopeptides, TEL, and three ﬂ uoroquinolones 
(TFLX, GFLX, and MFLX) showed strong activities (MIC90 
≤ 0.5 μg/ml) against these S. pneumoniae strains, regardless 
of their different susceptibilities to PCG. On the other 
hand, aminoglycosides were substantially less active, as 
expected, against S. pneumoniae, with MIC50s of 8.0–64 μg/
ml (Table 3). Except for 2 isolates, 164 strains (98.8%) of 
PSSP were susceptible to IPM, whereas 39 strains (50.0%) 
of PISP and 10 strains (76.9%) of PRSP were IPM-resistant 
(including intermediate resistance). Regarding macrolide 
resistance, 77.1% of PSSP, 84.6% of PISP, and all strains of 
PRSP were EM-resistant.
Susceptibility of PSSP
Among the β-lactams, CCL and CAZ showed high MIC90s 
(4.0 and 8.0 μg/ml, respectively) while the MIC90s of the 
other β-lactams were ≤1.0 μg/ml. Particularly, TAZ/PIPC 
and all carbapenems showed markedly strong activities, 
with MIC90s of ≤0.06 μg/ml. With regard to the ﬂ uoroquino-
lones, CPFX, LVFX, and PZFX showed moderate activities 
(MIC50s of = 2.0–4.0 μg/ml), though TFLX, GFLX, and 
MFLX were very active.
Susceptibility of PISP
Penicillins, including combinations with β-lactamase inhibi-
tors, were relatively weak against PISP, with MIC90s of 1.0 
or 2.0 μg/ml. Among the oral cephems, CFPN and CDTR 
showed relatively strong activities, with MIC90s of 1.0 and 
0.5 μg/ml, respectively, while CCL and CFDN were less 
active, with MIC90s of 64 and 4.0 μg/ml, respectively. The 
activities of parenteral cephems were found to be moderate 
to relatively weak, with MIC90s ranging from 1.0 to 8.0 μg/
ml. The MIC90s of four carbapenems, IPM, MEPM, BIPM, 
and DRPM, were ≤0.5μg/ml.
With regard to the ﬂ uoroquinolones, the MIC90s of 
TFLX, GFLX, and MFLX were 0.25, 0.5, and 0.25 μg/ml, 
respectively, while that of CPFX, LVFX, and PZFX was 
2.0 μg/ml. The activities of macrolide-lincosamide antibiot-
ics against PISP were found to be very weak (MIC90s of 
≥128 μg/ml), except that TEL showed strong activity (MIC90 
of 0.25 μg/ml).
Susceptibility of PRSP
Although the number of PRSP strains examined in this 
study was small (13 strains), some tendencies in susceptibil-
ity were noted. The strains were highly susceptible to 
PAPM, MEPM, BIPM, DRPM, FRPM, TFLX, GFLX, 
MFLX, TEL, and VCM (MIC90s of 0.25–0.5 μg/ml), but they 
were relatively less susceptible to CFDN, CEZ, CTM, CAZ, 
CMZ, and MINO (MIC50s of 8.0–32 μg/ml).
Findings for Haemophilus inﬂ uenzae
Susceptibilities of 206 H. inﬂ uenzae strains to 39 antibacte-
rial agents were determined. The results of susceptibility 
testing of H. inﬂ uenzae isolates are summarized in Table 4. 
According to the CLSI breakpoint for ABPC,2 91 H. inﬂ u-
enzae strains (44.2%) were found to be ABPC-susceptible, 
41 (19.9%) to be ABPC-intermediate, and 74 (35.9%) to be 
ABPC-resistant strains. With the use of the Nitroceﬁ n disks, 
all ABPC-intermediate and 60 (29.1%) ABPC-resistant 
strains were found to be β-lactamase-non-producing, and 
they were deﬁ ned as BLNAI and BLNAR, respectively. 
The remaining 14 ABPC-resistant strains were found to be 
β-lactamase-producing and were designated as BLPAR. 
The MIC50 and MIC90 values of PCG and ABPC for BLPAR 
isolates were at least ﬁ vefold higher than those for BLNAR 
isolates. However, there were no differences in the MIC50 
and MIC90 values of SBT/ABPC and CVA/AMPC among 
BLNAR isolates and BLPAR isolates. Regardless of their 
susceptibility to ABPC, all of the H. inﬂ uenzae strains were 
extremely susceptible to all six ﬂ uoroquinolones (MIC50s ≤ 
0.06 μg/ml).
Susceptibility of ABPC-susceptible strains
Of the 33 antibacterial agents other than ﬂ uoroquinolones, 
11 agents (PIPC, TAZ/PIPC, CFPN, CDTR, CAZ, CTRX, 
CFPM, AZT, MEPM, DRPM, and MINO) showed strong 
activities, with MIC90s of ≤0.5 μg/ml.
Susceptibility of BLNAI and BLNAR strains
The BLNAI and BLNAR strains were found to be substan-
tially susceptible (MIC90 ≤ 0.5 μg/ml) to PIPC, TAZ/PIPC, 
CDTR, CTRX, MEPM, and MINO. Among the cephems, 
CCL, CEZ, CTM, CZOP, and CMZ were less or not active 
against BLNAI and BLNAR, showing MIC90s of 64 and 64, 
64 and 128, 64 and 64, 8 and 16, and 16 and 32 μg/ml, 
respectively.
Susceptibility of BLPAR strains
Although the number of BLPAR was small (eight strains), 
some tendencies in susceptibility were noted. β-Lactamase 
inhibitors markedly restored the activities of penicillins 
against these strains: SBT decreased the MIC90 of ABPC 
from ≥256 to 8.0 μg/ml and TAZ decreased the MIC90 of 
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PSSP (PCG  0.06 μg/ml)
n = 166
PISP (PCG  0.125 μg/ml, 1 μg/ml)
n = 78
PRSP (PCG  2 μg/ml)
n = 13
MIC (μg/ml) MIC (μg/ml) MIC (μg/ml) MIC (μg/ml)
50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range
PCG 0.06 1 0.06–4 0.06 0.06 0.06–0.06 0.5 1 0.125–1 2 2 2–4
ABPC 0.125 2 0.06–8 0.125 0.125 0.06–0.5 1 2 0.25–8 4 4 2–8
SBT/ABPC 0.125 2 0.06–8 0.125 0.125 0.06–0.25 1 2 0.125–8 4 4 1–8
CVA/AMPC 0.06 1 0.06–8 0.06 0.125 0.06–0.25 0.5 1 0.125–4 1 2 0.5–8
PIPC 0.06 2 0.06–4 0.06 0.125 0.06–1 1 2 0.06–2 2 4 1–4
TAZ/PIPC 0.06 1 0.06–4 0.06 0.125 0.06–0.5 1 2 0.06–2 2 4 1–4
CCL 1 32 0.06–256 0.5 4 0.06–8 16 64 0.5–128 64 128 32–256
CFDN 0.25 4 0.06–16 0.125 1 0.06–2 2 4 0.06–16 4 8 2–8
CFPN 0.25 0.5 0.06–4 0.125 0.5 0.06–2 0.5 1 0.06–2 0.5 1 0.5–4
CDTR 0.125 0.5 0.06–1 0.06 0.25 0.06–1 0.25 0.5 0.06–1 0.5 1 0.25–1
CEZ 0.25 2 0.06–32 0.125 0.5 0.06–1 2 2 0.25–4 4 8 2–32
CTM 0.25 4 0.06–16 0.25 1 0.06–2 2 4 0.25–8 4 8 2–16
CAZ 4 8 0.06–32 2 8 0.06–32 4 8 0.25–32 8 16 4–32
CTRX 0.25 1 0.06–4 0.25 1 0.06–2 0.5 1 0.125–2 1 2 0.5–4
CFPM 0.25 1 0.06–2 0.25 1 0.06–2 0.5 1 0.125–2 1 2 0.5–2
CZOP 0.25 1 0.06–4 0.125 1 0.06–2 0.5 1 0.06–2 1 2 0.5–4
CMZ 0.5 8 0.06–32 0.5 1 0.06–2 4 8 0.5–32 8 32 8–32
IPM 0.06 0.25 0.06–2 0.06 0.06 0.06–0.25 0.125 0.5 0.06–0.5 0.25 1 0.125–2
PAPM 0.06 0.125 0.06–1 0.06 0.06 0.06–0.25 0.06 0.25 0.06–0.5 0.25 0.5 0.06–1
MEPM 0.06 0.25 0.06–2 0.06 0.06 0.06–0.25 0.25 0.5 0.06–0.5 0.5 0.5 0.25–2
BIPM 0.06 0.25 0.06–2 0.06 0.06 0.06–0.125 0.125 0.25 0.06–0.5 0.25 0.5 0.125–2
DRPM 0.06 0.25 0.06–1 0.06 0.06 0.06–0.125 0.125 0.25 0.06–0.5 0.25 0.5 0.125–1
FRPM 0.06 0.25 0.06–1 0.06 0.06 0.06–0.25 0.25 0.5 0.06–0.5 0.25 0.5 0.25–1
GM 4 8 1–16 4 8 1–16 4 8 2–8 4 8 4–8
AMK 32 64 8–128 32 64 8–128 32 64 16–128 64 64 32–128
ABK 16 32 2–64 16 32 2–64 16 32 4–32 16 32 8–32
CPFX 1 2 0.06–64 1 2 0.06–32 1 2 0.25–64 1 2 0.5–2
LVFX 1 2 0.5–64 1 2 0.5–32 1 2 0.5–64 1 2 0.5–2
TFLX 0.25 0.25 0.06–32 0.25 0.25 0.06–32 0.125 0.25 0.06–32 0.125 0.25 0.125–0.25
GFLX 0.25 0.5 0.06–16 0.25 0.5 0.06–8 0.25 0.5 0.125–16 0.25 0.25 0.25–0.5
PZFX 2 4 0.06–128 2 4 0.06–64 2 2 1–128 2 2 2–4
MFLX 0.25 0.5 0.06–8 0.25 0.5 0.06–4 0.25 0.25 0.125–8 0.25 0.25 0.25–0.5
MINO 8 16 0.06–64 4 16 0.06–64 8 8 0.06–32 8 16 0.5–16
EM 256 256 0.06–256 256 256 0.06–256 256 256 0.06–256 256 256 2–256
CAM 128 128 0.06–128 128 128 0.06–128 128 128 0.06–128 128 128 1–128
AZM 128 128 0.06–128 128 128 0.06–128 128 128 0.06–128 128 128 1–128
TEL 0.06 0.25 0.06–4 0.06 0.25 0.06–4 0.06 0.25 0.06–1 0.125 0.5 0.06–0.5
CLDM 64 256 0.06–256 64 256 0.06–256 32 256 0.06–256 16 256 0.06–256
VCM 0.25 0.25 0.06–0.5 0.25 0.25 0.06–0.5 0.25 0.25 0.125–0.5 0.25 0.25 0.25–0.25
LZD 0.5 1 0.25–2 0.5 1 0.25–2 1 1 0.25–2 1 1 0.5–1









BLNAS (ABPC  1 μg/ml, 
β-lactamase(−)) n = 91
BLNAI (ABPC = 2 μg/ml, 
β-lactamase(−)) n = 41
BLNAR (ABPC  4 μg/ml, 
β-lactamase(−)) n = 60
BLPAR (ABPC  4 μg/ml, 
β-lactamase(+)) n = 14
MIC (μg/ml) MIC (μg/ml) MIC (μg/ml) MIC (μg/ml) MIC (μg/ml)
50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range
PCG 2 8 0.06–256 0.25 2 0.06–16 4 8 2–8 4 8 2–16 128 256 8–256
ABPC 2 8 0.25–256 0.5 1 0.25–1 2 2 2–2 4 8 4–16 128 256 16–256
SBT/ABPC 2 8 0.06–16 0.25 1 0.06–1 2 2 1–4 4 8 2–8 4 8 2–16
CVA/AMPC 2 8 0.25–32 0.5 2 0.25–8 2 4 1–8 8 16 2–16 8 16 1–32
PIPC 0.06 0.25 0.06–256 0.06 0.125 0.06–1 0.125 0.25 0.06–0.5 0.125 0.25 0.06–0.5 128 256 16–256
TAZ/PIPC 0.06 0.125 0.06–1 0.06 0.06 0.06–1 0.06 0.25 0.06–0.5 0.06 0.125 0.06–0.5 0.06 0.25 0.06–0.25
CCL 8 64 0.25–128 2 16 0.25–32 16 64 4–128 32 64 4–128 16 64 4–128
CFDN 1 8 0.06–16 0.25 1 0.06–4 2 8 0.5–16 4 8 1–16 2 8 0.25–16
CFPN 0.5 2 0.06–8 0.06 0.125 0.06–1 1 2 0.06–4 2 4 0.125–4 0.5 4 0.06–8
CDTR 0.125 0.25 0.06–2 0.06 0.06 0.06–2 0.125 0.25 0.06–0.25 0.25 0.25 0.06–0.5 0.125 0.25 0.06–2
CEZ 8 64 0.25–256 4 16 0.25–64 8 64 1–256 32 128 1–256 8 64 2–128
CTM 4 64 0.25–128 1 8 0.25–32 16 64 4–64 32 64 2–128 4 64 2–128
CAZ 0.25 0.5 0.06–4 0.125 0.25 0.06–0.5 0.25 1 0.125–2 0.5 1 0.125–4 0.25 1 0.06–2
CTRX 0.125 0.25 0.06–0.5 0.06 0.06 0.06–0.5 0.25 0.25 0.06–0.5 0.25 0.5 0.06–0.5 0.125 0.5 0.06–0.5
CFPM 0.5 2 0.06–16 0.125 0.25 0.06–2 1 2 0.25–4 2 4 0.5–4 1 4 0.125–16
CZOP 4 8 0.06–64 0.125 1 0.06–4 8 8 0.5–32 8 16 2–64 4 32 0.125–32
CMZ 4 16 0.5–64 2 8 0.5–16 8 16 2–32 8 32 4–64 4 8 2–32
AZT 0.25 2 0.06–16 0.06 0.25 0.06–0.5 0.5 2 0.06–4 1 2 0.125–16 0.5 2 0.06–2
IPM 1 2 0.06–8 0.5 2 0.06–4 0.5 2 0.06–4 1 4 0.06–8 1 4 0.25–4
PAPM 0.5 2 0.06–4 0.5 1 0.06–2 0.5 2 0.06–2 1 4 0.06–4 1 2 0.125–4
MEPM 0.125 0.25 0.06–1 0.06 0.125 0.06–0.25 0.125 0.25 0.06–0.5 0.25 0.5 0.06–1 0.125 0.5 0.06–1
BIPM 1 4 0.06–8 0.5 2 0.06–8 2 4 0.06–4 4 8 0.06–8 2 4 0.25–8
DRPM 0.125 1 0.06–2 0.06 0.25 0.06–0.5 0.25 0.5 0.06–1 0.5 1 0.06–2 0.25 2 0.06–2
FRPM 1 2 0.125–4 0.5 2 0.125–2 2 2 0.25–4 2 4 0.25–4 2 2 0.25–4
GM 1 2 0.06–2 1 2 0.125–2 1 2 0.5–2 1 2 0.06–2 1 2 0.5–2
AMK 4 8 0.5–8 4 8 0.5–8 4 8 2–8 4 8 2–8 4 4 2–8
ABK 4 4 0.5–4 4 4 0.5–4 4 4 1–4 4 4 1–4 2 4 1–4
CPFX 0.06 0.06 0.06–16 0.06 0.06 0.06–4 0.06 0.06 0.06–16 0.06 0.06 0.06 0.06 0.125 0.06–1
LVFX 0.06 0.06 0.06–8 0.06 0.06 0.06–4 0.06 0.06 0.06–8 0.06 0.06 0.06 0.06 0.125 0.06–4
TFLX 0.06 0.06 0.06–32 0.06 0.06 0.06–1 0.06 0.06 0.06–32 0.06 0.06 0.06 0.06 0.06 0.06–0.5
GFLX 0.06 0.06 0.06–8 0.06 0.06 0.06–2 0.06 0.06 0.06–8 0.06 0.06 0.06 0.06 0.06 0.06–2
PZFX 0.06 0.06 0.06–32 0.06 0.06 0.06–2 0.06 0.06 0.06–32 0.06 0.06 0.06–0.125 0.06 0.06 0.06–4
MFLX 0.06 0.06 0.06–8 0.06 0.06 0.06–4 0.06 0.06 0.06–8 0.06 0.06 0.06–0.125 0.06 0.125 0.06–2
MINO 0.25 0.5 0.125–8 0.25 0.5 0.125–2 0.25 0.5 0.125–1 0.25 0.5 0.125–1 0.5 8 0.125–8
EM 4 8 0.25–32 4 4 0.25–16 4 8 1–16 4 8 0.5–32 4 4 2–8
CAM 8 16 0.5–64 8 8 2–32 8 32 2–32 8 16 0.5–64 4 32 2–32
AZM 0.5 1 0.125–4 0.5 1 0.25–4 0.5 2 0.25–4 1 1 0.125–4 0.5 1 0.125–1
TEL 2 4 0.25–8 1 2 0.25–8 2 4 0.5–8 2 4 0.25–8 1 2 0.5–4
CLDM 8 16 0.5–128 4 16 0.5–64 8 16 1–128 8 16 2–32 8 64 2–64
Susceptibilities of the 206 strains of H. inﬂ uenzae to 39 antimicrobial agents were studied. The number of strains and proportions of BLNAS, BLNAI, BLNAR, and BLPAR were 91 (44.2%), 
41 (19.9%), 60 (29.1%), and 14 (6.7%), respectively
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PIPC from ≥256 to 0.25 μg/ml. Among the cephems, CDTR 
and CTRX showed appreciable activity, with MIC90s of 0.25 
and 0.5 μg/ml, respectively.
Findings for Moraxella catarrhalis
Susceptibilities of 120 M. catarrhalis strains to 39 antibacte-
rial agents were tested. β-Lactamase inhibitors restored the 
activities of penicillins against these strains: SBT decreased 
the MIC90 of ABPC from 16 to 0.25 μg/ml and TAZ 
decreased the MIC90 of PIPC from 16 to ≤0.06 μg/ml. 
Although AMPC was not included in the panel, CVA was 
thought to restore the activity of AMPC, because the MIC90 
of CVA/AMPC was low (0.5 μg/ml). Four of ﬁ ve carbapen-
ems (PAPM, MEPM, BIPM, and DRPM), AZM, MINO, 
and all six ﬂ uoroquinolones showed strong activities, with 
MIC90s of ≤0.06–0.125 μg/ml. The activities of IPM, CAM, 
and TEL were also strong, with MIC90s of 0.25 μg/ml. 
Several cephems (CFDN, CFPN, CDTR, CTRX, CAZ, and 
CMZ), three aminoglycosides (GM, AMK, and ABK), and 
EM showed MIC90s of 0.25–1.0 μg/ml (Table 5).
Findings for Klebsiella pneumoniae
Susceptibilities of 122 K. pneumoniae strains to 34 antibac-
terial agents were determined. The agents that showed very 
strong activity (MIC90s ≤ 0.06 μg/ml) were MEPM and 
DRPM. Two oral cephems, CFDN and CDTR, ﬁ ve paren-
teral cephems (CTM, CAZ, CTRX, CFPM, and CZOP), 
three carbapenems (IPM, PAPM, and BIPM), two amino-
glycosides, GM and ABK, and four ﬂ uoroquinolones 
(CPFX, TFLX, GFLX, and PZFX), showed relatively 
strong activities, with MIC90s of 0.125–0.5 μg/ml (Table 6).
Findings for Pseudomonas aeruginosa
The antibacterial activities of 22 agents against 171 P. aeru-
ginosa strains were measured. Two aminoglycosides, GM 
and ABK, and one of six ﬂ uoroquinolones, CPFX, showed 
moderate activities, with MIC90s of 4.0 μg/ml. Two carbap-
enems, MEPM and DRPM, and two ﬂ uoroquinolones, 
LVFX and PZFX, showed MIC90s of 8.0 μg/ml. The MIC90s 
of three parenteral cephems (CAZ, CFPM, and CZOP), 
two carbapenems, IPM and BIPM, and two ﬂ uoroquino-
lones, TFLX and GFLX, were 16 μg/ml, while the MIC90s 
of the remainder of the agents ranged from 32 to 
≥256 μg/ml.
Only one strain was identiﬁ ed as multidrug-resistant P. 
aeruginosa (MDRP) from its proﬁ le of resistance to IPM, 
AMK, and CPFX (Table 7).
Cica-Beta Test (Kanto Chemical) in K. pneumoniae and 
P. aeruginosa
No ESBL-producing strain was detected in the 122 K. pneu-
moniae strains by the Cica-beta test. In the 171 P. aerugi-
nosa strains, the test revealed two strains of MBL-producing 
P. aeruginosa, including one multidrug-resistant strain.
Discussion
Because there was no accessible public database of the 
susceptibility of bacterial pathogens to contemporaneously 
used antibacterial agents in Japan, the Japanese Society of 
Chemotherapy (JSC) established a nationwide surveillance 
network in 2006 so that the data obtained through the sur-
veillance would enable the JSC to construct a database.
Our research focuses on major bacterial respiratory 
infections, so the collection of bacterial strains was limited 
to the seven species S. aureus, S. pneumoniae, S. pyogenes, 
H. inﬂ uenzae, M. catarrhalis, K. pneumoniae, and P. aeru-
ginosa. It is desirable that the analysis of antimicrobial 
susceptibility is conducted with those bacterial strains that 
really caused the infection. Therefore, we collected the 





PCG 16 32 0.06–64
ABPC 8 16 0.06–64
SBT/ABPC 0.25 0.25 0.06–0.5
CVA/AMPC 0.25 0.5 0.06–0.5
PIPC 8 16 0.06–64
TAZ/PIPC 0.06 0.06 0.06
CCL 2 8 0.25–32
CFDN 0.25 0.5 0.06–2
CFPN 0.5 0.5 0.06–1
CDTR 0.25 1 0.06–2
CEZ 4 8 0.25–32
CTM 1 2 0.25–4
CAZ 0.125 0.25 0.06–0.5
CTRX 0.5 1 0.06–4
CFPM 1 4 0.125–4
CZOP 2 4 0.125–8
CMZ 0.5 1 0.06–2
AZT 2 2 0.25–4
IPM 0.06 0.25 0.06–0.5
PAPM 0.06 0.125 0.06–0.25
MEPM 0.06 0.06 0.06
BIPM 0.06 0.06 0.06–0.25
DRPM 0.06 0.06 0.06
FRPM 0.25 0.5 0.06–1
GM 0.25 0.25 0.06–0.25
AMK 0.5 1 0.25–2
ABK 0.25 0.25 0.125–0.5
CPFX 0.06 0.06 0.06–0.5
LVFX 0.06 0.125 0.06–1
TFLX 0.06 0.06 0.06
GFLX 0.06 0.06 0.06–0.25
PZFX 0.06 0.06 0.06–0.5
MFLX 0.125 0.125 0.06–0.25
MINO 0.125 0.125 0.06–0.5
EM 0.5 0.5 0.125–256
CAM 0.125 0.25 0.06–128
AZM 0.06 0.06 0.06–64
TEL 0.125 0.25 0.06–64
CLDM 4 8 0.5–256
Susceptibilities of the 120 strains of M. catarrhalis to 39 antimicrobial 
agents were studied
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ABPC 64 256 1–256
SBT/ABPC 4 8 0.5–128
CVA/AMPC 2 4 1–32
PIPC 8 16 0.5–256
TAZ/PIPC 2 4 0.25–256
CCL 0.5 1 0.25–256
CFDN 0.125 0.25 0.06–64
CFPN 0.5 1 0.125–4
CDTR 0.25 0.5 0.06–32
CEZ 1 2 0.5–128
CTM 0.125 0.5 0.06–64
CAZ 0.125 0.25 0.06–64
CTRX 0.06 0.125 0.06–8
CFPM 0.06 0.125 0.06–2
CZOP 0.06 0.125 0.06–8
CMZ 0.5 2 0.5–16
AZT 0.06 0.125 0.06–64
IPM 0.25 0.5 0.06–1
PAPM 0.25 0.5 0.06–1
MEPM 0.06 0.06 0.06–0.125
BIPM 0.25 0.5 0.06–1
DRPM 0.06 0.06 0.06–0.25
FRPM 0.5 1 0.25–4
GM 0.25 0.5 0.125–128
AMK 1 2 0.25–2
ABK 0.5 0.5 0.25–1
CPFX 0.06 0.5 0.06–8
LVFX 0.125 1 0.06–4
TFLX 0.06 0.25 0.06–4
GFLX 0.06 0.5 0.06–8
PZFX 0.06 0.25 0.06–2
MFLX 0.25 1 0.06–16
MINO 2 4 0.25–64
AZM 8 8 1–32
Susceptibilities of the 122 strains of K. pneumoniae to 34 antimicrobial 
agents were studied
clinical isolates from adult patients with well-diagnosed 
respiratory tract infections.
The ﬁ rst year that surveillance was conducted the survey 
was done with the limited scope of respiratory tract infec-
tions in adults during the period from January to August, 
2006. A total of 952 strains were collected at 32 institutions 
throughout Japan, and 887 strains (93.2%) were found to 
be evaluable, via re-identiﬁ cation and cultivation at the 
central reference laboratory, for their susceptibilities to 
antibacterial agents.
The total numbers of strains we used for the ﬁ rst and 
second yearly surveillance studies were 887 and 1108, 
respectively. The reason for the increase in the number of 
strains may be the increase in the number of participating 
institutions, from 32 in the ﬁ rst year to 39 in the second year. 
The numbers of each species tested in the ﬁ rst period and 
the second yearly surveillance were as follows: S. aureus 
(205, 226), S. pneumoniae (200, 257), H. inﬂ uenzae (165, 
206), P. aeruginosa (143, 171), M. catarrhalis (91, 120), K. 
pneumoniae (74, 122), and S. pyogenes (9, 6). These results 
suggest that the numbers of each species in the second 
yearly surveillance had generally increased by 10% to 30% 
compared to the numbers in the ﬁ rst surveillance period. 
We noticed that the increase in the number of K. pneu-
moniae strains at 64.8%, was the highest among these 
species. Although we cannot give any clear reason for this 
difference, we think we should observe further changes in 
the types of respiratory pathogens.
With regard to S. aureus strains, their susceptibilities 
were analyzed according to their classiﬁ cation as MSSA and 
MRSA. Approximately 55% of MSSA were thought to be 
penicillinase-producing strains because of their resistance 
to ABPC and susceptibility to SBT/ABPC and CCL, and 
10.9% of them were thought to be emr-harboring strains 
because of their resistance to macrolides – EM, CAM, and 
AZM – and susceptibility to TEL (so-called ketolide lacking 
a sugar moiety to be recognized by emr resistance mecha-
nism).5 The difference between the resistance of MSSA to 
GM (10.9%) and that to AMK (1.1%) implied the coexis-
tence of aac(6′)/aph(2″)-harboring GM-resistant strains 
with aad(4′, 4″)-harboring AMK-resistant strains.6
The incidence of MRSA was high, at 59.7%, a ﬁ nding 
that is similar to the data reported by Mochizuki et al.7 
according to analyses via WHONET 5. These MRSA strains 
were susceptible to ABK, VCM, TEIC, and LZD, except 
that a few strains were somewhat less susceptible (MIC 
8.0 μg/ml) to ABK; these strains may possess both the 
aph(3′)-III and aac(6′)/aph(2″) genes, as reported recently.6 
Although the emergence of MRSA resistant to VCM, 
TEIC, or LZD has already been reported in Japan, such a 
resistant strain was not detected in the present 
surveillance.
Regarding S. pneumoniae, the proportion of PSSP/PISP/
PRSP was found to be 65: 30: 5. The proportion of each 
group of strains remained at a level similar to that in the 





PIPC 8 128 0.25–256
TAZ/PIPC 4 64 0.06–256
CAZ 2 16 0.125–128
CTRX 64 256 0.5–256
CFPM 4 16 0.25–256
CZOP 2 16 0.125–256
AZT 4 32 0.06–128
IPM 2 16 0.25–128
PAPM 8 32 0.25–256
MEPM 1 8 0.06–256
BIPM 0.5 16 0.06–128
DRPM 0.5 8 0.06–128
GM 2 4 0.06–64
AMK 4 8 0.25–128
ABK 2 4 0.125–64
CPFX 0.25 4 0.06–128
LVFX 1 8 0.06–256
TFLX 0.5 16 0.06–32
GFLX 1 16 0.06–256
PZFX 0.5 8 0.06–256
MFLX 2 16 0.25–256
MINO 16 64 0.5–256
Susceptibilities of the 171 strains of P. aeruginosa to 22 antimicrobial 
agents were analyzed
166 
ﬁ rst year of surveillance (61: 35: 4). More than 60% of the 
PSSP were thought to be emr-harboring strains because of 
their resistance to macrolides (EM, CAM, and AZM) and 
CLDM, and their susceptibility to the ketolide TEL. As for 
PISP, their incidence (30%) in this survey of adult RTI was 
much lower than that (50.8%) reported in pediatric infec-
tions.8–10 In general, the antimicrobial susceptibilities of 
PISP were somewhat lower than those of PSSP: the acti-
vities of penicillins, including those combined with β-
lactamase inhibitors, against PISP were 8 to 32 times less 
than those against PSSP; among the cephems, CCL, CFDN, 
CEZ, CTM, and CMZ showed activities 8 to 16 times less 
than those against PSSP, while CDTR, CAZ, CTRX, 
CFPM, CFPN, and CZOP showed 2 to 4 times less activity 
against PISP than against PSSP; the activities of carbapen-
ems against PISP were 4 times less than those against PSSP. 
The activities of ﬂ uoroquinolones, glycopeptides, and LZD 
against PISP were the same as those against PSSP.
The incidence of PRSP was very low (5.0%) in the 
present surveillance of adult RTI, as compared with 
the incidence (16.9%-49.0%) reported in pediatric infec-
tions.8–10 This difference is thought to be attributable to the 
excess usage of oral penicillins and cephems for the treat-
ment of children, because ﬂ uoroquinolones (except for nor-
ﬂ oxacin) are contraindicated in children in Japan. The 
pattern of susceptibility of PRSP strains somewhat resem-
bled that of PISP, however, PRSP were substantially sus-
ceptible (MIC90s ≤ 0.5 μg/ml) only to carbapenems, except 
for IPM, TFLX, GFLX, MFLX, TEL, and VCM.
The FDA has raised the concentration at which S. pneu-
moniae is considered to be susceptible to penicillin for the 
treatment of pneumonia, although the susceptibility break-
point for meningitis remains unchanged (0.06 μg/ml). With 
the new criteria for breakpoint MICs, only 1 (0.4%) of the 
257 S. pneumoniae strains in the present study was found 
to be intermediate-resistant, and the remainder (256 strains; 
99.6%) were classiﬁ ed as susceptible strains. These results 
suggest that penicillin is still effective against community-
acquired pneumonia caused by S. pneumoniae.
Concerning H. inﬂ uenzae, half of the strains showed 
decreased susceptibility to ABPC without production of β-
lactamase; BLNAI (19.9%) and BLNAR (29.1%). The inci-
dence of BLNAI in adults is thought to be somewhat lower 
than that in children (30.4%).11
All six ﬂ uoroquinolones demonstrated extremely strong 
activity (MIC90 ≤ 0.06 μg/ml) against H. inﬂ uenzae strains, 
regardless of the strains’ ABPC-susceptibility. Of the rest 
of the agents, PIPC, TAZ/PIPC, CDTR, CTRX, MEPM, 
and MINO showed strong activities (MIC90s of 0.125–0.5 μg/
ml) against BLNAI and BLNAR, and TAZ markedly 
restored the activity of PIPC against BLPAR (MIC90 
decreased from ≥256 μg/ml to 0.25 μg/ml).
By means of a recently established method, the Cica-
Beta Test 1 (Kanto Chemical), for the detection of extended-
spectrum β-lactamases (ESBL) and metallo-β-lactamases 
(MBL), two strains of P. aeruginosa were identiﬁ ed to be 
MBL-producing, although we did not ﬁ nd ESBL-producing 
K. pneumoniae. Such a low incidence of ESBL- and MBL-
producing strains may be attributable to the target of our 
surveillance being limited to adult RTI; a higher incidence 
of such strains was reported in clinical isolates from urinary 
tract infections.12
The information on the patients’ backgrounds and clini-
cal settings supplied by the participating institutions enabled 
the JSC Surveillance Committee to analyze the collected 
pathogens in more detail; the results of this analysis will be 
published elsewhere.
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